We Welcome you for 15th World Summit on Alzheimer’s Disease, Dementia Care Research and Awareness on November 30-December 01, 2020
The Alzheimer’s disease is currently ranked as the sixth leading cause of death in the United States, but recent estimates indicate that the disorder may rank third, just behind heart disease and cancer, as a cause of death for older people.
Alzheimer’s is the most common cause of dementia among older adults. Dementia is the loss of cognitive functioning—thinking, remembering, and reasoning—and behavioral abilities to such an extent that it interferes with a person’s daily life and activities. Dementia ranges in severity from the mildest stage, when it is just beginning to affect a person’s functioning, to the most severe stage, when the person must depend completely on others for basic activities of daily living.
The causes of dementia can vary, depending on the types of brain changes that may be taking place. Other dementias include Lewy body dementia, frontotemporal disorders, and vascular dementia. It is common for people to have mixed dementia—a combination of two or more types of dementia. For example, some people have both Alzheimer’s disease and vascular dementia.
Alzheimer’s disease is named after Dr. Alois Alzheimer. In 1906, Dr. Alzheimer noticed changes in the brain tissue of a woman who had died of an unusual mental illness. Her symptoms included memory loss, language problems, and unpredictable behavior. After she died, he examined her brain and found many abnormal clumps (now called amyloid plaques) and tangled bundles of fibers (now called neurofibrillary, or tau, tangles).
These plaques and tangles in the brain are still considered some of the main features of Alzheimer’s disease. Another feature is the loss of connections between nerve cells (neurons) in the brain. Neurons transmit messages between different parts of the brain, and from the brain to muscles and organs in the body.
Young Scientist Benefits:
- Our conferences provide best Platform for your research through oral presentations.
- Share the ideas with both eminent researchers and mentors.
- Young Scientist Award reorganization certificate and memento to the winners
- Young Scientists will get appropriate and timely information by this Forum.
- Platform for collaboration among young researchers for better development
- Award should motivate participants to strive to realize their full potential which could in turn be beneficial to the field as whole.
Changes in the Brain
Scientists continue to unravel the complex brain changes involved in the onset and progression of Alzheimer’s disease. It seems likely that changes in the brain may begin a decade or more before memory and other cognitive problems appear. During this preclinical stage of Alzheimer’s disease, people seem to be symptom-free, but toxic changes are taking place in the brain. Abnormal deposits of proteins form amyloid plaques and tau tangles throughout the brain. Once-healthy neurons stop functioning, lose connections with other neurons, and die. Many other complex brain changes are thought to play a role in Alzheimer’s, too.
The damage initially appears to take place in the hippocampus and the entorhinal cortex, parts of the brain essential in forming memories. As more neurons die, additional parts of the brain are affected and begin to shrink. By the final stage of Alzheimer’s, damage is widespread, and brain tissue has shrunk significantly.
Signs and Symptoms
Memory problems are typically one of the first signs of cognitive impairment related to Alzheimer’s disease. Some people with memory problems have a condition called mild cognitive impairment (MCI). In MCI, people have more memory problems than normal for their age, but their symptoms do not interfere with their everyday lives. Movement difficulties and problems with the sense of smell have also been linked to MCI. Older people with MCI are at greater risk for developing Alzheimer’s, but not all of them do. Some may even go back to normal cognition.
The first symptoms of Alzheimer’s vary from person to person. For many, decline in non-memory aspects of cognition, such as word-finding, vision/spatial issues, and impaired reasoning or judgment, may signal the very early stages of Alzheimer’s disease. Researchers are studying biomarkers (biological signs of disease found in brain images, cerebrospinal fluid, and blood) to detect early changes in the brains of people with MCI and in cognitively normal people who may be at greater risk for Alzheimer’s. Studies indicate that such early detection is possible, but more research is needed before these techniques can be used routinely to diagnose Alzheimer’s disease in everyday medical practice.
Mild Alzheimer’s Disease
As Alzheimer’s disease progresses, people experience greater memory loss and other cognitive difficulties. Problems can include wandering and getting lost, trouble handling money and paying bills, repeating questions, taking longer to complete normal daily tasks, and personality and behavior changes. People are often diagnosed in this stage.
Moderate Alzheimer’s Disease
In this stage, damage occurs in areas of the brain that control language, reasoning, sensory processing, and conscious thought. Memory loss and confusion grow worse, and people begin to have problems recognizing family and friends. They may be unable to learn new things, carry out multistep tasks such as getting dressed, or cope with new situations. In addition, people at this stage may have hallucinations, delusions, and paranoia and may behave impulsively.
Severe Alzheimer’s Disease
Ultimately, plaques and tangles spread throughout the brain, and brain tissue shrinks significantly. People with severe Alzheimer’s cannot communicate and are completely dependent on others for their care. Near the end, the person may be in bed most or all of the time as the body shuts down.
or reload the browser
Alzheimer’s Drugs Market by Drug Class (Cholinergic, Memantine, and Combined Drug) and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Sales): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017 - 2024”. According to the report, global Alzheimer’s Drugs Market was valued at approximately USD 3.64 billion in 2017 and is expected to generate revenue of around USD 5.66 billion by end of 2024, growing at a CAGR of around 8% between 2018 and 2024.
Alzheimer’s is a neurodegenerative progressive disease. Alzheimer's disease is a type of dementia which includes a broad group of brain diseases, such as problems with memory, thinking, and behavior for the long term. It is a type of dementia and near about 60-70% of Alzheimer's disease is the cause of dementia. Many researchers consider an increase in the level of protein amyloid in the brain is one of the causes of Alzheimer disease. Older age is the prominent cause of Alzheimer's, whereas there are also some genetic and some other causes of Alzheimer diseases. The exact cause of Alzheimer’s disease is still unknown.
Browse through 90 Tables & 12 Figures spread over 110 Pages and in-depth TOC on “Global Alzheimer’s Drugs Market Size & Share 2017: Industry Type, Growth, Segments Analysis and Forecast 2024”.
The global Alzheimer’s market is mainly driven by the growing occurrence of diseases in developed countries specifically in the Western region. Additionally, the prevalence of some neurodegenerative diseases such as dementia, growing occurrence of diseases, firm government encouragement for Alzheimer’s drug development, and growing alertness about the treatment of Alzheimer’s disease is resulting into increased demand for Alzheimer’s drugs market. However, high prices of the advance drugs may create restraints in underdeveloped countries. Also, awareness about Alzheimer’s disease in the developing regions remains restricted, which has resulted in unbalanced healthcare systems and obstructive research infrastructure. In Asia Pacific region, growing encouragement for mental care by governments is anticipated to drive the Alzheimer’s drugs market in the near future.
The report covers forecast and analysis for the Alzheimer’s drugs market on a global and regional level. The study provides historical data from 2015 along with a forecast from 2018 to 2024 based on revenue (USD Billion). The study includes drivers and restraints for the Alzheimer’s drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Alzheimer’s drugs market on a global level.
In order to give the users of this report a comprehensive view on the Alzheimer’s drugs market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses drug class, distribution channel, and regional segmentation are benchmarked based on their market size, growth rate, and general attractiveness.
The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the market on the global and regional basis.
This report segments the global Alzheimer’s drugs market as follows:
Global Alzheimer’s Drugs: by Drug Class
Global Alzheimer’s Drugs: by Distribution Channel
Global Alzheimer’s Drugs: by Region
The Middle East and Africa
or reload the browser
To share your views and research, please click here to register for the Conference.
All accepted abstracts will be published in respective Our International Journals.
Abstracts will be provided with Digital Object Identifier by